Literature DB >> 16416159

Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice.

Graciela N Balerio1, Ester Aso, Rafael Maldonado.   

Abstract

RATIONALE: Acute behavioural effects and motivational responses induced by nicotine can be modulated by the endocannabinoid system supporting the existence of a physiological interaction between these two systems.
OBJECTIVES: The present study was designed to examine the possible involvement of the cannabinoid system in the anxiolytic- and anxiogenic-like responses induced by nicotine in mice.
METHODS: Animals were only exposed once to nicotine. The acute administration of low (0.05) or high (0.8 mg/kg, s.c.) doses of nicotine produced opposite effects in the elevated plus-maze, i.e. anxiolytic- and anxiogenic-like responses, respectively. The effects of the pretreatment with the CB1 cannabinoid receptor antagonist, rimonabant (0.25, 0.5 and 1 mg/kg, i.p.), and the cannabinoid agonist, delta9-tetrahydrocannabinol (delta9-THC, 0.1 mg/kg, ip), were evaluated on the anxiolytic- and anxiogenic-like responses induced by nicotine.
RESULTS: Rimonabant completely abolished nicotine-induced anxiolytic-like effects and increased the anxiogenic-like responses of nicotine, suggesting an involvement of CB1 receptors in these behavioural responses. On the other hand, delta9-THC failed to modify nicotine anxiolytic-like responses but attenuated its anxiogenic-like effects. In addition, the association of non-effective doses of delta9-THC and nicotine produced clear anxiolytic-like responses.
CONCLUSIONS: These results demonstrate that the endogenous cannabinoid system is involved in the regulation of nicotine anxiety-like behaviour in mice and provide new findings to support the use of cannabinoid antagonists in the treatment of tobacco addiction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16416159     DOI: 10.1007/s00213-005-0251-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  48 in total

1.  Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine.

Authors:  Emmanuel Valjent; Jennifer M Mitchell; Marie-Jo Besson; Jocelyne Caboche; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Effect of acute administration of nicotine on in vivo release of noradrenaline in the hippocampus of freely moving rats: a dose-response and antagonist study.

Authors:  M P Brazell; S N Mitchell; J A Gray
Journal:  Neuropharmacology       Date:  1991-08       Impact factor: 5.250

3.  Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence.

Authors:  A Castañé; E Valjent; C Ledent; M Parmentier; R Maldonado; O Valverde
Journal:  Neuropharmacology       Date:  2002-10       Impact factor: 5.250

4.  Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat.

Authors:  M Navarro; E Hernández; R M Muñoz; I del Arco; M A Villanúa; M R Carrera; F Rodríguez de Fonseca
Journal:  Neuroreport       Date:  1997-01-20       Impact factor: 1.837

5.  Effects of cannabinoids on levels of acetylcholine and choline and on turnover rate of acetylcholine in various regions of the mouse brain.

Authors:  H L Tripathi; F J Vocci; D A Brase; W L Dewey
Journal:  Alcohol Drug Res       Date:  1987

6.  Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).

Authors:  Caroline Cohen; Ghislaine Perrault; Guy Griebel; Philippe Soubrié
Journal:  Neuropsychopharmacology       Date:  2005-01       Impact factor: 7.853

7.  Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test.

Authors:  J D Brioni; A B O'Neill; D J Kim; M W Decker
Journal:  Eur J Pharmacol       Date:  1993-07-06       Impact factor: 4.432

8.  Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats.

Authors:  G T Pryor; F F Larsen; S Husain; M C Braude
Journal:  Pharmacol Biochem Behav       Date:  1978-03       Impact factor: 3.533

9.  Detection by in vivo microdialysis of nicotine-induced norepinephrine secretion from the hypothalamic paraventricular nucleus of freely moving rats: dose-dependency and desensitization.

Authors:  B M Sharp; S G Matta
Journal:  Endocrinology       Date:  1993-07       Impact factor: 4.736

10.  The effects of nicotine on locomotor activity in non-tolerant and tolerant rats.

Authors:  P B Clarke; R Kumar
Journal:  Br J Pharmacol       Date:  1983-02       Impact factor: 8.739

View more
  28 in total

Review 1.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

2.  Genetic and pharmacological approaches to evaluate the interaction between the cannabinoid and cholinergic systems in cognitive processes.

Authors:  S A Bura; A Castañé; C Ledent; O Valverde; R Maldonado
Journal:  Br J Pharmacol       Date:  2007-02-05       Impact factor: 8.739

Review 3.  Negative affective states and cognitive impairments in nicotine dependence.

Authors:  F Scott Hall; Andre Der-Avakian; Thomas J Gould; Athina Markou; Mohammed Shoaib; Jared W Young
Journal:  Neurosci Biobehav Rev       Date:  2015-06-06       Impact factor: 8.989

4.  Influence of nicotine on doxorubicin and cyclophosphamide combination treatment-induced spatial cognitive impairment and anxiety-like behavior in rats.

Authors:  Yoshihisa Kitamura; Erika Kanemoto; Misaki Sugimoto; Ayumi Machida; Yuka Nakamura; Nanami Naito; Hirotaka Kanzaki; Ikuko Miyazaki; Masato Asanuma; Toshiaki Sendo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-01-07       Impact factor: 3.000

Review 5.  The role of fatty acid amide hydrolase inhibition in nicotine reward and dependence.

Authors:  Pretal P Muldoon; Aron H Lichtman; Loren H Parsons; M Imad Damaj
Journal:  Life Sci       Date:  2012-06-12       Impact factor: 5.037

Review 6.  Interactions between the endocannabinoid and nicotinic cholinergic systems: preclinical evidence and therapeutic perspectives.

Authors:  Maria Scherma; Anna Lisa Muntoni; Miriam Melis; Liana Fattore; Paola Fadda; Walter Fratta; Marco Pistis
Journal:  Psychopharmacology (Berl)       Date:  2016-01-04       Impact factor: 4.530

7.  Nicotine dependence predicts cannabis use disorder symptoms among adolescents and young adults.

Authors:  Lisa Dierker; Jessica Braymiller; Jennifer Rose; Renee Goodwin; Arielle Selya
Journal:  Drug Alcohol Depend       Date:  2018-04-16       Impact factor: 4.492

8.  Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts.

Authors:  Ziva D Cooper; Margaret Haney
Journal:  Drug Alcohol Depend       Date:  2009-05-14       Impact factor: 4.492

9.  Delta-9-tetrahydrocannabinol enhances food reinforcement in a mouse operant conflict test.

Authors:  Maria Flavia Barbano; Anna Castañé; Elena Martín-García; Rafael Maldonado
Journal:  Psychopharmacology (Berl)       Date:  2009-05-19       Impact factor: 4.530

10.  Smoking tobacco along with marijuana increases symptoms of cannabis dependence.

Authors:  Geoffrey L Ream; Ellen Benoit; Bruce D Johnson; Eloise Dunlap
Journal:  Drug Alcohol Depend       Date:  2008-03-12       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.